Annika Gustafson

Annika Gustafson

Auto-generated profile, based on publicly available information

Annika Gustafson

Medical Scientist Training Program, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SPShanshan Pei
Shanshan Pei
DPDaniel A. Pollyea
Daniel A. Pollyea
AGAnnika Gustafson
Annika Gustafson
BSBrett M. Stevens
Brett M. Stevens
MMMohammad Minhajuddin
Mohammad Minhajuddin
CJCraig T. Jordan
Craig T. Jordan
Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well as relapse following initial response demonstrates the need for a deeper understanding of resistance mechanisms. In the present study, we report that responses to venetoclax +azacitidine in patients with AML correlate closely with developmental stage, where phenotypically primitive AML is sensitive, but monocytic AML is more resistant. Mechanistically, resistant monocytic AML has a distinct transcriptomic profile, loses expression of venetoclax target BCL2, and relies on MCL1 to mediate oxidative phosphorylation and survival. This differential sensitivity drives a selective process in patients which favors the outgrowth of monocytic subpopulations at relapse. Based on these findings, we conclude that resistance to venetoclax + azacitidine can arise due to biological properties intrinsic to monocytic differentiation. We propose that optimal AML therapies should be designed so as to independently target AML subclones that may arise at differing stages of pathogenesis. Significance: Identifying characteristics of patients who respond poorly to venetoclax-based therapy and devising alternative therapeutic strategies for such patients are important topics in AML. We show that venetoclax resistance can arise due to intrinsic molecular/metabolic properties of monocytic AML cells and that such properties can potentially be targeted with alternative strategies.

9 May 2025 in Science Advances
Verified
Journal Article
Open access
SRSheera R. Rosenbaum
Sheera R. Rosenbaum
CHConnor J. Hughes
Connor J. Hughes
KFKaiah M. Fields
Kaiah M. Fields
SPStephen Connor Purdy
Stephen Connor Purdy
AGAnnika L. Gustafson
Annika L. Gustafson
HFHeide L. Ford
Heide L. Ford
Triple-negative breast cancer cells must evade immune surveillance to metastasize to distant sites, yet this process is not well understood. The Eyes absent (EYA) family of proteins, which are crucial for embryonic development, become dysregulated in cancer, where they have been shown to mediate proliferation, migration, and invasion. Our study reveals an unusual mechanism by which EYA3 reduces the presence of cytotoxic natural killer (NK) cells in the premetastatic niche (PMN) to enhance metastasis, independent of its effects on the primary tumor. We find that EYA3 up-regulates nuclear factor κB signaling to enhance CCL2 expression, which, in contrast to previous findings, suppresses cytotoxic NK cell activation in vitro and their infiltration into the PMN in vivo. These findings uncover an unexpected role for CCL2 in inhibiting NK cell responses at the PMN and suggest that targeting EYA3 could be an effective strategy to reactivate antitumor immune responses to inhibit metastasis.

3 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSheera R. Rosenbaum
Sheera R. Rosenbaum
CHConnor J. Hughes
Connor J. Hughes
KFKaiah M. Fields
Kaiah M. Fields
SPStephen Connor Purdy
Stephen Connor Purdy
AGAnnika Gustafson
Annika Gustafson
HFHeide L. Ford
Heide L. Ford
Patients with Triple Negative Breast Cancer (TNBC) exhibit high rates of metastases and poor prognoses. The Eyes absent (EYA) family of proteins are developmental transcriptional cofactors/phosphatases that are re-expressed and/or upregulated in numerous cancers. Herein, we demonstrate that EYA3 correlates with decreased survival in breast cancer, and that it strongly, and specifically, regulates metastasis via a novel mechanism that involves NF-kB signaling and an altered innate immune profile at the pre-metastatic niche (PMN). Remarkably, restoration of NF-kB signaling downstream of Eya3 knockdown (KD) restores metastasis without restoring primary tumor growth, isolating EYA3/NF-kB effects to the metastatic site. We show that secreted CCL2, regulated downstream of EYA3/NF-kB, specifically decreases cytotoxic NK cells in the PMN and that re-expression of Ccl2 in Eya3 -KD cells is sufficient to rescue activation/levels of cytotoxic NK cells in vitro and at the PMN, where EYA3-mediated decreases in cytotoxic NK cells are required for metastatic outgrowth. Importantly, analysis of public breast cancer datasets uncovers a significant correlation of EYA3 with NF-kB/CCL2, underscoring the relevance of EYA3/NF-kB/CCL2 to human disease. Our findings suggest that inhibition of EYA3 could be a powerful means to re-activate the innate immune response at the PMN, inhibiting TNBC metastasis. Significance: EYA3 promotes metastasis of TNBC cells by promoting NF-kB-mediated CCL2 expression and inhibiting cytotoxic NK cells at the pre-metastatic niche, highlighting a potential therapeutic target in this subset of breast cancer.

3 April 2023
Verified
Other
Open access
SPShanshan Pei
Shanshan Pei
DPDaniel A. Pollyea
Daniel A. Pollyea
AGAnnika Gustafson
Annika Gustafson
BSBrett M. Stevens
Brett M. Stevens
MMMohammad Minhajuddin
Mohammad Minhajuddin
CJCraig T. Jordan
Craig T. Jordan
Supplementary Tables S1-S6 describing patient characteristics, gene lists, LSC signatures, and reagents.

3 April 2023
Verified
Other
Open access
SPShanshan Pei
Shanshan Pei
DPDaniel A. Pollyea
Daniel A. Pollyea
AGAnnika Gustafson
Annika Gustafson
BSBrett M. Stevens
Brett M. Stevens
MMMohammad Minhajuddin
Mohammad Minhajuddin
CJCraig T. Jordan
Craig T. Jordan
Supplementary Figures S1-S5 supporting Main Figures 1-5.

3 April 2023
Verified
Other
Open access
SPShanshan Pei
Shanshan Pei
DPDaniel A. Pollyea
Daniel A. Pollyea
AGAnnika Gustafson
Annika Gustafson
BSBrett M. Stevens
Brett M. Stevens
MMMohammad Minhajuddin
Mohammad Minhajuddin
CJCraig T. Jordan
Craig T. Jordan
Supplementary Figures S1-S5 supporting Main Figures 1-5.